"Designing Growth Strategies is in our DNA"
The global orthobiologics market size was USD 5,830.1 million in 2018 and is projected to reach USD 8,261.6 million by 2026, exhibiting a CAGR of 4.5% in the forecast period (2019-2026).
The economic burden due to orthopedic injuries and osteoarthritis is increasing at a significant rate. According to the Centers for Disease Control and Prevention (CDC), over 30 Mn people in the U.S. are affected by osteoarthritis, making it a major concern for healthcare providers. This shows that the demand for orthobiologics is likely to augment in the forecast period.
Orthobiologics have considerably impacted orthopedic surgeries. Orthobiologics, which was earlier used for regenerative medicines, has now expanded its area of application to spinal fusion, dental, maxillofacial, cartilage repair, knee arthroscopies and many others, thus impacting the orthobiologics market demand. The increasing demand and rapid adoption of the newly introduced products such as Medtronic’s Infuse, a bone morphogenetic protein, etc., are primary reasons for the surge in the market.
Get comprehensive study about this report by, request a free sample copy
"High demand for viscosupplements to surge the global market"
Viscosupplements are injections of hyaluronic acid, which are directly administered into the joints. Viscosupplements are extensively used in the treatment of knee osteoarthritis, which is one of the major problems among the geriatric population. High product costs, entries of the new manufacturers, and recent marketing approvals are the factors attributed to the expansion of viscosupplements.
Furthermore, improving reimbursement guidelines for viscosupplements are also favoring the viscosupplements segments. Considering the aforementioned factors, the high demand for viscosupplements is anticipated to drive the orthobiologics market growth during the forecast period.
To get details on market share, speak to our analyst
Based on the product, the global orthobiologics market segments include viscosupplements, bone growth stimulators, demineralized bone matrix, synthetic bone substitutes, stem cells, allograft, and others. Belonging to the first generation of orthobiologics, viscosupplements dominated the market in 2018 with a share of 32.1% in the global market. Based on applications, the global market segments include spinal fusion, maxillofacial & dental, soft tissue repair, reconstructive & fracture surgery, and others.
Spinal fusion accounted for the highest market share in 2018, owing to the increased use of synthetic matrices and allografts in spine fusion surgeries. Soft tissue repair segment witnessed the highest growth due to the increased cases of sports injuries and demand for orthobiologics for cartilage repair. Based on end user, the global market segments include hospitals, ambulatory surgical centers, and specialty clinics. The rising demand for orthobiologics among these end-users is anticipated to foster the orthobiologics market share in the forecast years.
"Growing Trend of Orthopedic Surgery in Outpatient Settings to Favor the Market in North America"
The orthobiologics market in North America was valued at USD 2,326.2 Mn in 2018 and is estimated to dominate the market throughout the forecast period. Business strategies of leading manufacturers in the U.S., favorable reimbursement policies, increasing prevalence of degenerative bone diseases and growing trend of orthopedic surgeries in outpatient settings are the factors that may boost the orthobiologics market in North America during 2019-2026.
In terms of revenues, Europe is projected to be the second dominant region with a significant share in the global orthobiologics market owing to the new marketing approval for Cingal, a viscosupplements in Europe. Asia Pacific is expected to register the highest CAGR during the forecast period, which is attributable to the increasing demand for viscosupplements in India and rising number of standalone orthopedic clinics. Latin America and the Middle East & Africa are expected to witness a considerable market potential in the forecast period owing to the rising demand for treatment of sports injuries and an increase in government initiatives for awareness of orthobiologics.
North America Orthobiologics Market, 2018
To get geographical overview of this market, request a free sample copy
"Medtronic and Sanofi to lead the Orthobiologics Market"
Medtronic has emerged as the leading player in the global orthobiologics industry, mainly due to the successful launch and rapid adoption for Infuse bone morphogenetic protein. Medtronic is estimated to hold the highest share in the forecast duration owing to the higher cost and strong sales force for Infuse and FDA approval received for the use of Infuse in new spine surgery indication in April 2018. Enabled by these initiatives, the orthobiologics market revenue is likely to spur in the forthcoming years. Other players operating in the global market are DePuy Synthes (Johnson & Johnson Services, Inc.), Stryker, Zimmer Biomet, Sea Spine, Bioventus, RTI Surgical Holdings, Inc., Musculoskeletal Transplant Foundation, Wright Medical Group N.V., and Anika Therapeutics, Inc.
The rising number of reconstructive and regenerative surgeries have resulted in increased demand for orthobiologic products. Orthobiologics are the products that are used during surgeries to aid quick healing of orthopedic injuries. Orthobiologics are made from products ranges from growth stimulators to synthetic bone substitutes.
The report provides qualitative and quantitative insights on the orthobiologics industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented based on product type, application, end user, and geography. In terms of product type, the global market is segmented into viscosupplements, bone growth stimulators (Bone Morphogenetic Proteins and Platelet-Derived Growth Factors), demineralized bone matrix (DBM), synthetic bone substitutes, stem cells, allografts, and others.
On the basis of application, the market is categorized into spinal fusion, maxillofacial & dental, soft tissue repair, reconstructive & fracture surgery, and others. The end-users for orthobiologic products include hospitals, ambulatory surgical centres, and specialty clinics. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.
To get information on various segments, share your queries with us
Along with this, the report analysis includes orthobiologics market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of soft tissue injuries for key countries, number of spinal fusion surgery for key countries, regulatory scenario in key countries, new product launch, key mergers and acquisitions: recent industry developments, and others.
By Product Type
By End User
Fortune Business Insights says that the orthobiologics market was valued at USD 5,830.1 Million in 2018 and is projected to reach USD 8,261.6 Million by 2026.
In 2018, the North America orthobiologics market was valued at USD 2,326.2 Million.
Growing at a CAGR of 4.5%, the market will exhibit significant growth in the forecast period (2019-2026)
The viscosupplements segment is expected to be the leading segment in this market during the forecast period.
Increasing applications of orthobiologics and rising demand for viscosupplements are the major factors driving the orthobiologics market.
Medtronic and Sanofi are the top players in the market.
North America is expected to hold the highest market share in the market.
The introduction of new products in the market and rising number of spinal fusion surgeries are the factors that are expected to drive the adoption of orthobiologics.
Increased research on Bone Morphogenetic Proteins (BMP) and use of stem cells and grafts for soft tissue repair are trends of the orthobiologics market